Business
First Patient recruited in Phase III ARDS Study
First Patient recruited in Phase III ARDS Study.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 2492K Faron Pharmaceuticals Oy 29 December 2015 \n \n\nFaron Pharmaceuticals Oy\n(\"Faron\" or the \"Company\")\n \nFirst Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome \n \nTURKU - FINLAND, 29 December 2015 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce the enrolment of the first patient in the Phase III INTEREST clinical programme for Traumakine® for the treatment of acute respiratory distress syndrome (\"ARDS\").\nARDS is a severe orphan disease with a reported mortality rate of approximately 30-45%, for which there is currently no approved pharmacological treatment. It is characterised by widespread capillary leakage and inflammation in the lungs, most often as a result of sepsis, pneumonia or significant trauma. In the earlier completed Phase I/II trial in respect of Traumakine® the drug candidate was associated with an 81% reduction in the odds of 28-day mortality. Traumakine® has been granted Orphan Drug Designation in Europe which allows a period of 10 years of market exclusivity following marketing approval by the EMA.\nThe recruitment of the first patient, so soon after the Company's recent IPO, is consistent with the anticipated timeline of 12 to 18 months required to complete recruitment for the pivotal Phase III trial for Traumakine®. The Phase III trial is being led by Professor Geoff Bellingan from University College London Hospital and Professor Marco Ranieri from the University of Rome.\nDr Markku Jalkanen, CEO of Faron said: \"Following our successful IPO, we very much welcome the commencement of patient recruitment for the pivotal Phase III trial for this awful condition, ARDS which has significant unmet medical needs. Our previous exceptional results with an 81% reduction in odds of 28-day mortality of ARDS patients have excited our clinical network, which we expect will facilitate completion of patient recruitment within the anticipated time frame of 12-18 months. We believe that Traumakine® presents a significant opportunity for those suffering from ARDS, the hospitals which treat them and the societies covering the recovery of ARDS patients.\"\nThe Phase III clinical trial INTEREST is a double-blinded, randomised, parallel-g...